


PRODUCT INFORMATION



Escitalopram

Item No. 22405

CAS Registry No.: 128196-01-0
Formal Name: (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile
Synonym: (S)-Citalopram
MF: C₂₀H₂₁FN₂O
FW: 324.4
Purity: ≥98%
UV/Vis.: λ_{max}: 241 nm
Supplied as: A solution in ethanol
Storage: -20°C
Stability: ≥2 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Escitalopram is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of escitalopram in these solvents is approximately 33 and 25 mg/ml, respectively.

Escitalopram is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the ethanolic solution of escitalopram should be diluted with the aqueous buffer of choice. Escitalopram has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method.

Description

Escitalopram is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and the (S) isomer of citalopram (Item No. 14572) and (R)-citalopram.¹ It selectively binds to SERT (K_i = 0.89 nM) over the norepinephrine and dopamine transporters (K_is = >10,000 and 8,150 nM, respectively) and inhibits 5-HT reuptake in rat brain synaptosomes (IC₅₀ = 2.1 nM).^{2,3} Escitalopram reduces immobility in the forced swim test in mice (ED₅₀ = 12 mg/kg), indicating anti-depressant-like activity, and increases exploratory behavior in the black-and-white box test in mice with a minimal effective dose (MED) of 0.49 mg/kg, indicating anxiolytic-like activity.⁴ Escitalopram (20 μM) prevents acid sphingomyelinase activation and subsequent ceramide release induced by infection with replication-deficient vesicular stomatitis virus pseudoviral particles (pp-VSV) presenting the severe acute respiratory coronavirus 2 (SARS-CoV-2) spike protein in Vero cells, an effect that can be overcome with exogenous application of C16 ceramide (Item No. 10681).⁵ Formulations containing escitalopram have been used in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

References

1. Höschl, C. and Svestka, J. *Expert Rev. Neurother.* **8**(4), 537-552 (2008).
2. Zhang, P., Cyriac, G., Kopajtic, T., et al. *J. Med. Chem.* **53**(16), 6112-6121 (2010).
3. Sánchez, C., Bøgesø, K.P., Ebert, B., et al. *Psychopharmacology (Berl)* **174**(2), 163-176 (2004).
4. Sánchez, C., Bergqvist, P.B.F., Brennum, L.T., et al. *Psychopharmacol. (Berl)*. **167**(4), 353-362 (2003).
5. Carpinteiro, A., Edwards, M.J., Hoffmann, M., et al. *Cell Rep. Med.* **1**(8), 100142 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM